|
|
★ ★
小木虫(金币+0.5):给个红包，谢谢回帖
zhychen2008(金币+1, DRDEPI+1): 多谢提供信息 2011-09-03 16:03:22
Meantime, Eisai and Toyama Chemical Co have submitted a marketing authorisation application for T-614 (iguratimod), an anti-rheumatic agent being jointly developed in Japan by the two companies.
T-614 is a novel disease modifying anti-rheumatic drug originally discovered by Toyama and an MAA was previously submitted in 2003. However, the application was temporarily withdrawn in 2009 in order to conduct an additional clinical study which subsequently confirmed with statistical significance the efficacy of the agent as an add-on therapy for use with the standard of care, methotrexate.
http://www.pharmatimes.com/Artic ... epsy_portfolio.aspx
只能说是先声的运气好了。。。
[ Last edited by hardee on 2011-9-1 at 15:17 ] |
|
回复此楼
点击这里搜索更多相关资源